COBENFY

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Sep 26, 2024

   1 yr 9 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Sep 26, 2029

   in 3 yr 4 mo

4. Patent 10238643 expires

   Listed drug product patent expiration.

   Jul 21, 2030

   in 4 yr 2 mo

5. Patent 10265311 expires

   Listed method-of-use patent (U-3513) expiration.

   Jul 21, 2030

   in 4 yr 2 mo

6. Patent 10369143 expires

   Listed method-of-use patent (U-3513) expiration.

   Jul 21, 2030

   in 4 yr 2 mo

7. Patent 10369144 expires

   Listed drug product patent expiration.

   Jul 21, 2030

   in 4 yr 2 mo

8. Patent 10695339 expires

   Listed method-of-use patent (U-3513) expiration.

   Jul 21, 2030

   in 4 yr 2 mo

9. Patent 10925832 expires

   Listed drug product patent expiration.

   Sep 27, 2039

   in 13 yr 6 mo

10. Patent 10933020 expires

    Listed drug product patent expiration.

    Sep 27, 2039

    in 13 yr 6 mo

11. Patent 11452692 expires

    Listed method-of-use patent (U-3513) expiration.

    Sep 27, 2039

    in 13 yr 6 mo

12. Patent 11471413 expires

    Listed method-of-use patent (U-3513) expiration.

    Sep 27, 2039

    in 13 yr 6 mo

13. Patent 11890378 expires

    Listed drug product patent expiration.

    Sep 27, 2039

    in 13 yr 6 mo

14. Patent 12558317 expires

    Listed drug product patent expiration.

    Oct 29, 2039

    in 13 yr 7 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  Sep 26, 2029

  in 3 yr 4 mo

Listed patents (11)